Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

To get a sense of who is truly in control of C3.ai, Inc. , it is important to understand the ownership structure of the business. We can see that institutions own the lion's share ...

Investors are hopeful that C3.ai (NYSE: AI) can deliver results similar to Palantir (NASDAQ: PLTR). *Stock prices used were the afternoon prices of July 23, 2025. The video was published on July 25, ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

Artificial intelligence companies are largely cheering President Trump’s “AI Action Plan” issued this week — no surprise, ...